{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colonic+Cancer&page=21", "query": { "condition": "Colonic Cancer", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 3054, "total_pages": 306, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colonic+Cancer&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colonic+Cancer&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T21:59:37.911Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03890731", "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Cancer" ], "interventions": [ { "name": "BAY73-4506 (Regorafenib, Stivarga)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-04-02", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03890731" }, { "nct_id": "NCT02538627", "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "MM-151", "type": "DRUG" }, { "name": "MM-121", "type": "DRUG" }, { "name": "MM-141", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-08", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 5, "location_summary": "Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538627" }, { "nct_id": "NCT07715903", "title": "Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms", "Neoplasms", "Intrahepatic Cholangiocarcinoma", "Adrenocortical Carcinoma", "Metastasis, Neoplasm" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2026-10-28", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07715903" }, { "nct_id": "NCT03374254", "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil [5-FU]", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2018-02-16", "completion_date": "2023-07-18", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 10, "location_summary": "Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374254" }, { "nct_id": "NCT03190941", "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Gastric Cancer", "Gastrointestinal Cancer", "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Anti-KRAS G12V mTCR PBL", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 110, "start_date": "2017-09-21", "completion_date": "2028-06-29", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190941" }, { "nct_id": "NCT02877056", "title": "Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Endoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2005-08", "completion_date": "2023-08", "has_results": false, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02877056" }, { "nct_id": "NCT00006046", "title": "Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "monoclonal antibody hu3S193", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2000-07-12", "completion_date": "2002-09-24", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006046" }, { "nct_id": "NCT04313114", "title": "The PRIME-CRC Trial to Promote CRC Screening in Rural Communities", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "health literacy appropriate education and demonstration", "type": "BEHAVIORAL" }, { "name": "shared decision making", "type": "BEHAVIORAL" }, { "name": "automated call reminders or automated texts", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Louisiana State University Health Sciences Center Shreveport", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "45 Years to 75 Years" }, "enrollment_count": 804, "start_date": "2021-09-20", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 3, "location_summary": "Bastrop, Louisiana • Marion, Louisiana • Saint Joseph, Louisiana", "locations": [ { "city": "Bastrop", "state": "Louisiana" }, { "city": "Marion", "state": "Louisiana" }, { "city": "Saint Joseph", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04313114" }, { "nct_id": "NCT02301338", "title": "Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "Usual care", "type": "OTHER" }, { "name": "Phone Calls", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 2, "start_date": "2014-11", "completion_date": "2016-03-16", "has_results": false, "last_update_posted_date": "2017-03-13", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02301338" }, { "nct_id": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Esophageal Adenocarcinoma", "Cholangiocarcinoma", "Gallbladder Carcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-24T21:59:37.911Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430738" } ] }